Takayuki Matsumoto, Eri Takaoka, Keiko Ishida, Naoaki Nakayama, Eri Noguchi, Tsuneo Kobayashi, Katsuo Kamata
Index: Atherosclerosis 205(1) , 87-95, (2009)
Full Text: HTML
Thromboxane A(2) (TXA(2)) is thought to contribute to the development of diabetic complications. We tested the hypothesis that the impaired endothelial function seen in Otsuka Long-Evans Tokushima Fatty (OLETF) rats (a type 2 diabetic model) might be improved by chronic treatment with ozagrel, a TXA(2) synthase inhibitor. In mesenteric arteries from OLETF rats (40-46 weeks old) [vs. those from age-matched Long-Evans Tokushima Otsuka (LETO) rats]: (1) ACh-induced endothelium-dependent relaxation, NO-mediated relaxation, and endothelium-derived hyperpolarizing factor (EDHF)-type relaxation were all reduced; (2) ACh-induced cyclooxygenase-dependent contraction was enhanced; (3) endothelium-derived contracting factor (EDCF)-mediated contraction was enhanced; (4) ACh-stimulated nitrite production was reduced but the nitrate/nitrite ratio was increased; and (5) ACh-stimulated production of TXA(2) was increased. Chronic treatment with ozagrel (100mg/kg/day for 4 weeks, starting when they were 36-42 weeks of age) partly corrected the above abnormalities. These results suggest that ozagrel has normalizing effects on endothelial functions in OLETF mesenteric arteries, at least partly by increasing endothelium-derived relaxing factors (i.e., NO and EDHF) signaling and reducing EDCF signaling.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Ozagrel hydrochloride
CAS:78712-43-3 |
C13H15ClN2O3 |
Adhesion of platelets through thromboxane A₂ receptor signal...
2015-07-01 [Life Sci. 132 , 85-92, (2015)] |
BLT2 up-regulates interleukin-8 production and promotes the ...
2012-01-01 [PLoS ONE 7 , e49186, (2012)] |
Safety and efficacy of fasudil monotherapy and fasudil-ozagr...
2008-06-01 [Neurol. Med. Chir. (Tokyo) 48(6) , 241-7; discussion 247-8, (2008)] |
A prostacyclin agonist with thromboxane inhibitory activity ...
2010-02-01 [Clin. Exp. Allergy 40(2) , 317-26, (2010)] |
A selective thromboxane A2 (TXA2) synthase inhibitor, ozagre...
2009-10-01 [J. Pharmacol. Sci. 111(2) , 211-5, (2009)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved